SEC Form 4 · accession 0001104659-15-024666
T2 Biosystems, Inc. · TTOO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sarah O. Kalil
Officer — Chief Operating Officer
Period of report
Mar 27, 2015
Accepted (ET)
Mar 31, 2015 · 3:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492674
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.001 | Mar 27, 2015 | M | 41,500 | $3.22 | A | 56,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1 | $3.22 | Mar 27, 2015 | M | 41,500 | D | — | Sep 25, 2023 | Common Stock | 41,500 | 124,529 | D |
Explanation of responses
- F1This Stock Option was granted on September 25, 2013 and vesting commenced on August 12, 2013. Options to purchase 25% of the total underlying shares vested on the first anniversary of the vesting commencement date and options to purchase the remaining shares vest in 36 equal monthly installments thereafter.
- F2The reporting person's Form 3 filed on August 6, 2014, understated the number of shares underlying the derivative security by six shares. The number of derivative securities beneficially owned following the reported transaction disclosed herein corrects that error.